<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04765072</url>
  </required_header>
  <id_info>
    <org_study_id>VICC PED 2019</org_study_id>
    <secondary_id>3P30CA068485-24S2</secondary_id>
    <nct_id>NCT04765072</nct_id>
  </id_info>
  <brief_title>Expanding Rural Health Cancer Control Capacity</brief_title>
  <official_title>Expanding Rural Health Cancer Control Capacity: Focus on Cancer Survivorship</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Debra Friedman</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt-Ingram Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Through this pilot study, investigators will test an innovative approach to implement&#xD;
      survivorship care planning at three sites located in or adjacent to rural counties. The pilot&#xD;
      data will inform a subsequent multi-site Hybrid Type 3 Implementation-Effectiveness study&#xD;
      that will assess both implementation and clinical effectiveness outcomes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Aims:&#xD;
&#xD;
        -  Pilot test the implementation of guideline-based survivorship care planning in a rural&#xD;
           setting using patient navigation plus telehealth among underserved rural cancer&#xD;
           survivors. Investigators will collect feasibility data on patient recruitment rates and&#xD;
           the ability to measure clinical effectiveness outcomes using the electronic health&#xD;
           record and patient reports (survivor adherence to recommended disease surveillance,&#xD;
           health assessment and cancer prevention/early detection practices).&#xD;
&#xD;
        -  Identify the facilitators and barriers to future larger scale implementation of&#xD;
           guideline-based survivorship care planning in rural settings to optimize the&#xD;
           implementation strategies. Through a mixed methods approach, investigators will address&#xD;
           implementation research questions focused on &quot;real world&quot; implementation of the&#xD;
           guideline-based intervention in rural areas, including barriers/facilitators and&#xD;
           translation to other rural settings. This will allow us to optimize the implementation&#xD;
           strategies that will be further evaluated in the future large-scale implementation trial&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Anticipated">February 2029</completion_date>
  <primary_completion_date type="Anticipated">February 2028</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of improvement in adherence to survivorship plan (Survivorship Care Planning Experience Satisfaction Survey (1-5 Excellent - Poor)</measure>
    <time_frame>Approximately 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure effectiveness of Telehealth on survivorship care</measure>
    <time_frame>Approximately 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Estimate the facilitators to a future larger-scale implementation of guideline-based survivorship care planning in rural settings</measure>
    <time_frame>Approximately 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Estimate the barriers to a future larger-scale implementation of guideline-based survivorship care planning in rural settings</measure>
    <time_frame>Approximately 1 year</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Survivorship care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in rural areas will receive a telehealth (providing health-related services through electronic communication technologies) survivorship care plan in combination with assistance from a patient navigator.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Survivorship Patient Navigation Intervention</intervention_name>
    <description>Patient navigator assistance for navigating the healthcare system and locating and utilizing beneficial resources</description>
    <arm_group_label>Survivorship care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Telehealth Survivorship Visit Intervention</intervention_name>
    <description>Individualized survivorship care plan</description>
    <arm_group_label>Survivorship care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Cancer patient at least 18 years of age at time of cancer therapy&#xD;
&#xD;
          -  English-speaking with the ability to provide informed consent&#xD;
&#xD;
          -  Received treatment for Stage 0 - III cancer with curative intent&#xD;
&#xD;
          -  Completed cancer therapy within the previous 12 months (i.e., 12 months prior to&#xD;
             consenting) and in complete remission&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Debra Friedman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt-Ingram Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emma Schremp</last_name>
    <phone>(615)936-2156</phone>
    <email>emma.schremp@vumc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vanderbilt-Ingram Service for Timely Access</last_name>
    <phone>800-811-8480</phone>
    <email>cip@vumc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Baptist Cancer Center- Golden Triangle Columbus</name>
      <address>
        <city>Columbus</city>
        <state>Mississippi</state>
        <zip>39705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katie Baty</last_name>
      <phone>662-244-1760</phone>
    </contact>
    <investigator>
      <last_name>Phil Lammers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baptist Cancer Center - North Mississippi</name>
      <address>
        <city>Oxford</city>
        <state>Mississippi</state>
        <zip>38655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Mathews</last_name>
      <phone>662-636-4301</phone>
    </contact>
    <investigator>
      <last_name>Phil Lammers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baptist Cancer Center- Bartlett</name>
      <address>
        <city>Bartlett</city>
        <state>Tennessee</state>
        <zip>38133</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Talana Vogel</last_name>
      <phone>901-226-3019</phone>
    </contact>
    <investigator>
      <last_name>Phil Lammers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 12, 2021</study_first_submitted>
  <study_first_submitted_qc>February 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2021</study_first_posted>
  <last_update_submitted>February 17, 2021</last_update_submitted>
  <last_update_submitted_qc>February 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt-Ingram Cancer Center</investigator_affiliation>
    <investigator_full_name>Debra Friedman</investigator_full_name>
    <investigator_title>Sponsor Investigator</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

